APEX1 and breast carcinoma: The results indicated no relationship of APE1 Asp148Glu polymorphism with breast cancer risk (OR = 0.947, 95% CI = 0.829–1.082 for Asp/Glu vs. Asp/Asp; OR = 0.958, 95% CI = 0.813–1.129 for Glu/Glu vs. Asp/Asp; OR = 0.946, 95% CI = 0.835–1.072 for dominant model; OR = 1.004, 95% CI = 0.873–1.155 for recessive model) (Figure 3).